Compare Danaher Corporation (DHR) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs UiPath Inc — how do they compare? Danaher Corporation trades at $218.95 (market cap $152.87B), while UiPath Inc trades at $13.56 (market cap $6.91B). The key difference: Danaher Corporation is far larger — about 22.1× UiPath Inc's market cap, and Danaher Corporation pays a 0.74% dividend while UiPath Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and UiPath Inc for 139 Days on average.
| DHR | PATH | |
|---|---|---|
Market Cap | $152.87B | $6.91B |
Volume | 5,228,698 | 34,321,250 |
Sector | Health | Technology |
52-Week High | $242.05 | $19.29 |
52-Week Low | $161.91 | $9.38 |
Typical Hold Time | 69 Days | 139 Days |
Enterprise Value | $175.08B | $5.70B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
UiPath (PATH) trades at $13.07, down 0.23% with bearish technical signals despite strong fundamentals. The company shows improving financials with revenue growth from $1.43B in 2025 to projected $1.7B in 2026, transitioning to profitability with a 21.03% net margin. Recent partnerships with Snowflake and BDO highlight strategic positioning in AI automation, though technical indicators show resistance at $13 with RSI suggesting mixed momentum.
PATH offers compelling value with a P/E of 19.78 and analyst consensus target of $15.13 (16% upside), but faces execution risks and competitive pressure. The stock's bearish technical setup contrasts with fundamental improvement, creating potential for volatility. Investors should weigh strong profitability metrics against recent price weakness and mixed analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
